Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price gapped up prior to trading on Monday . The stock had previously closed at $85.00, but opened at $88.87. Novo Nordisk A/S shares last ...

On Monday, BMO Capital Markets adjusted its stance on Novo Nordisk (NYSE:NVO) shares following the release of Phase 3 clinical trial results for the company's diabetes treatment, CagriSema.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados decepcionantes de una de las drogas con las que esperaba superar a su ...

Novo Nordisk’s latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 ...

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday after it announced disappointing results of a new drug study.

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...